Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. The company is also developing nevanimibe, an ACAT1 inhibitor for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS).
If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!